WELCOME TO THE GVN INTRANET LOG IN Center Survey Step 1 of 6 16% This survey may be completed on behalf of one or multiple virology laboratories within your institution. If multiple laboratories exist, answer in aggregate where feasible and note key differences when capacities apply to only some labs. If a question applies to only a subset of laboratories, please indicate this briefly. Section 1: General Information & Contact Details Ayuda para traducir Aide à la traduction Institution/laboratory unit responding(Required)GVN designation(Required) Center of Excellence (CoE) Affiliate None Other (GVN Designation)What is the primary geographic scope at which your laboratory/laboratories typically engage with public health or surveillance activities?(Required) National (country-level mandate) Subnational/Regional (state/provincial/territorial level) Local/Municipal Multicountry or regional (serves multiple countries) Other Other (Geographic Scope)(Required)What type of institution do you represent?(Required) non-profit research institution non-profit organization academic research institution medical institution government agency Other Other (institution Do you Represent)(Required)Address(Required) City State / Province / Region AfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire, Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo VerdeCambodiaCameroonCanadaCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos IslandsColombiaComorosCongoCongo, Democratic Republic of theCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzechiaCôte d'IvoireDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEswatiniEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard Island and McDonald IslandsHoly SeeHondurasHong KongHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKorea, Democratic People's Republic ofKorea, Republic ofKuwaitKyrgyzstanLao People's Democratic RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacaoMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth MacedoniaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestine, State ofPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussian FederationRwandaRéunionSaint BarthélemySaint Helena, Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint MartinSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSint MaartenSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwedenSwitzerlandSyria Arab RepublicTaiwanTajikistanTanzania, the United Republic ofThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkmenistanTurks and Caicos IslandsTuvaluTürkiyeUS Minor Outlying IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited StatesUruguayUzbekistanVanuatuVenezuelaViet NamVirgin Islands, BritishVirgin Islands, U.S.Wallis and FutunaWestern SaharaYemenZambiaZimbabweÅland Islands Country Region: (Required)South AmericaCentral AmericaCaribbeanNorth AmericaSouth AsiaEast AsiaCentral AsiaNorth AsiaSoutheast AsiaWest AsiaAustraliaNorth AfricaWest AfricaEast AfricaCentral AfricaSouthern AfricaEuropeName(Required) First Last Primary Contact Person for this Survey:(Required)Title(Required)Email(Required) Phone(Required)WebsitePlease briefly describe your role and areas of expertise most relevant to institutional collaborations with public health (e.g., virology domains, surveillance, diagnostics, genomics, training)Bio (250 words or less):Highest degree:(Required) Bachelor’s degree (or equivalent) Master’s degree (or equivalent) Doctoral degree (e.g., PhD, DrPH, DSc) Medical degree (e.g., MD, MBBS) Other Other (Highest Degree) Section 2: Core Virology Expertise & Pathogen Focus Which of the following viral pathogens does your institution have significant expertise with (e.g., routine testing, research, surveillance)? Check the box for all that applies. Adenoviruses Arenaviruses (Lassa, Junín, Machupo, etc.) Chikungunya virus Coronaviruses (SARS-CoV-1, SARS-CoV-2, Middle East respiratory syndrome coronavirus, human coronaviruses 229E, NL63, OC43, or HKU1) Coxsackieviruses Crimean-Congo hemorrhagic fever virus (CCHFV) Cytomegalovirus (CMV) Dengue virus Eastern Equine Encephalitis virus (EEEV) Ebolaviruses Enteroviruses (including EV-D68, poliovirus) Epstein-Barr virus (EBV) Hantaviruses (e.g., Sin Nombre virus, Andes virus) Hepatitis A virus Hepatitis B virus Hepatitis C virus Hepatitis D virus Hepatitis E virus Herpes simplex virus 1 (HSV-1) Herpes simplex virus 2 (HSV-2) Human Immunodeficiency Virus (HIV) Human metapneumovirus (hMPV) Human papillomavirus (HPV) Human T-cell leukemia virus 1 (HTLV-1) Human T-cell leukemia virus 2 (HTLV-2) Influenza A virus Influenza B virus Influenza C virus Influenza D virus JC virus (John Cunningham virus) Lassa virus Marburgviruses Measles virus Monkeypox virus (Mpox) Mumps virus Norovirus Oropouche virus Parainfluenza viruses (types 1–4) Rabies virus Respiratory syncytial virus (RSV) Rhinoviruses Rift Valley fever virus Rotavirus Rubella virus Simian Foamy Virus Smallpox (Variola virus) Tick-borne encephalitis virus (TBEV) Varicella-zoster virus (VZV) Venezuelan Equine Encephalitis virus (VEEV) West Nile virus (WNV) Western Equine Encephalitis virus (WEEV) Yellow Fever virus Zika virus Other: please specify Name up to three virologists working with these viruses.Other (Viral Pathogens) Section 3: Infrastructure, Resources & Quality What Biosafety Level (BSL) facilities are at your institution? (Select all that apply) BSL-1 BSL-2 BSL-3 BSL-4 N/A (No virology work performed requiring specific BSLs) Does your center possess any of the following state-of-the-art facilities or specialized equipment highly relevant to virology research/diagnostics? (Select all that apply) Cryo-Electron Microscopy (Cryo-EM) suite Next-generation sequencing (NGS) platforms (e.g., Illumina NovaSeq, Oxford Nanopore PromethION) Advanced flow cytometers (e.g., multi-parameter cell sorters) Automated liquid handling systems High-throughput screening platforms Mass spectrometry for proteomics/metabolomics Dedicated animal facility (specify type if applicable, e.g., ABSL-3) Other significant equipment/facility) Other (Equipment)Which institutional data systems, if any, does your laboratory use? (Select all that apply) Laboratory Information Management System (LIMS Electronic Lab Notebook (ELN) Inventory management Asset management Data warehouse Integration of middleware Other (please specify): Other (Data Systems)How are analytical and sequencing data stored and backed up? Please indicate the retention period, storage type (on-premises/cloud), and backup frequency.Storage type: On‑premises Cloud Hybrid Backup frequency: Daily Weekly Monthly Other Other (Backup Frequency)Retention PeriodExample: 7 Years(Select all that apply) Do you have automated data transfer capabilities between instruments, LIMS (or alternative), or analysis pipelines? Yes — describe systems/flows No In progress (planned date) Yes - Describe systems/flows(Required)In progress (planned date)(which components are in place and current status of automated transfer)(Required)Approximate the number of full-time equivalent (FTE) staff dedicated to virology activities (including researchers, technicians, bioinformaticians, etc.). ≤ 10 11-30 31-60 61-99 100+ What formal training programs related to virology, genomics, or biosafety are offered by your institution? If available, include links to documents or websites.What formal competency framework, if any, do you use to assess virology or sequencing personnel? WHO CLSI National standard Internal framework Other Is your laboratory currently accredited by a recognized body for its virology operations? Yes, nationally accredited (e.g., CLIA, ISO 15189, CAP, etc.) Yes, internationally accredited (e.g., WHO-recognized, ISO 17025, etc.) Yes, accredited but nationally and internationally In process of seeking accreditation Not currently accredited Other If readily available, please upload documentary evidence of current lab accreditation (e.g., CLIA certificate, ISO 15189 scope, CAP certificate, or equivalent). Drop files here or Select files Max. file size: 50 MB. If unable to upload, please link documentary evidence of current lab accreditation (e.g., CLIA certificate, ISO 15189 scope, CAP certificate, or equivalent).Please provide the date of the certificate. MM slash DD slash YYYY If accreditation documentation cannot be shared, please provide a link to the public registry where your accreditation status can be verified.Under what regulatory authority is your lab permitted to conduct clinical diagnostic testing?Examples: CLIA, national public health authority, institutional authorization, or equivalent.Are you authorized to report diseases that are legally required to be reported to public health authorities under national or subnational regulations? Yes (specify which agencies) No Yes (specify which agencies)Are there institutional or national policies that limit your ability to perform clinical diagnostic testing? If yes, describe briefly. Yes (describe briefly) No Yes (describe briefly)Does your laboratory have a documented Quality Management System (QMS) for virology operations? Yes No Which Quality Management System (QMS) elements are formally documented and audited? Standard Operating Procedure (SOP) management Document control Corrective and Preventive Action (CAPA) Internal audits Management review Other Are you involved in mentorship programs or capacity-building initiatives for other laboratories (e.g., in your region, nationally, or globally)? Yes, at the subnational/regional (state/provincial/territorial level) level Yes, at the national level Yes, at a multicountry level (serving multiple countries) Yes, at the global/international level Yes, at multiple levels (please specify) No Not sure Yes, at multiple levels (please specify)Does your laboratory regularly communicate findings or information on viral diseases (including surveillance, diagnostics, or research findings) to any of the following audiences? General Public Healthcare Professionals Government/public health authorities International partners Other stakeholders (specify) Irregularly No Not sure Other stakeholders(Required)How Frequently? Real-time Weekly Monthly Ad hoc Are you involved in any community engagement activities related to viral disease prevention, awareness, or education? Yes No Not sure Yes (Explain Community Engagement)During an outbreak, what is your institution’s surge capacity for clinical care? Please indicate the maximum number of additional patients your facility can accommodate per day for outbreak-related illness. Fewer than 10 patients/day 10–49 patients/day 50–99 patients/day 100–249 patients/day 250+ patients/day Not applicable Not sure During an outbreak, what is your institution’s surge capacity for diagnostic processing? Please indicate the maximum number of samples/day your institution can process per day during peak outbreak respons Less than 100 tests/day 100–499 tests/day 500–999 tests/day 1,000–4,999 tests/day 5,000–9,999 tests/day 10,000+ tests/day Not applicable Not sure During an outbreak, what is your institution’s surge capacity for producing vaccines? We do not produce vaccines Less than 10,000 doses/week 10,000–99,999 doses/week 100,000–499,999 doses/week 500,000+ doses/week Not sure Vaccine Delivery/Administration Capacity. How many doses can your institution administer (or distribute through partners) per week? Less than 1,000 doses/week 1,000–9,999 doses/week 10,000–49,999 doses/week 50,000+ doses/week Not sure Section 4: Surveillance, Epidemiology & Response Does your center perform in-house viral genomic sequencing? (Check all that apply) Whole-genome sequencing Targeted sequencing (e.g., amplicon-based) Metagenomic sequencing No in-house sequencing performed [if selected skip to section 5] Outsourced to external lab/partner Other (please specify): Other (Center Perform in-house viral genomic sequencing)Does your center have in-house bioinformatics expertise for viral genomic data analysis? (Check all that apply) Phylogenetic analysis Variant calling Genome assembly Data visualization / dashboards No in-house bioinformatics expertise Other (please specify): Other (In-house bioinformatics expertise for viral genomic data analysis).Do you contribute sequence data to any of the following databases? (Check all that apply) GISAID GenBank / NCBI EMBL-EBI Local or national databases (specify) Do not submit data Other (please specify): Local or national databases (specify)(Required)Other (Contribute sequence data to any of the following databases)(Required)How frequently do you submit? Real-time Weekly Monthly Quarterly Ad hoc Does your laboratory provide real‑time or scheduled data feeds to public health authorities (case results, metadata, genomic data)? If yes, specify frequency and transport method. Yes No I don't know Other Which data exchange standards or protocols do you use? HL7 v2.x FHIR REST APIs SFTP None Other (specify) Other (protocols)Approximately how many viral genomes does your center sequence per year? < 100 100–499 500–1,999 2,000–9,999 10,000+ Not applicable / sequencing not performed What sequencing platforms does your center use? (Check all that apply) Illumina (e.g., MiSeq, NextSeq, NovaSeq) Oxford Nanopore Technologies (e.g., MinION, GridION) PacBio Ion Torrent Sanger sequencing Other (please specify): Other (Sequencing platforms does your center use)Does your laboratory actively participate in viral disease surveillance programs (e.g., sentinel surveillance, syndromic surveillance)? Yes No Yes (Explain Viral Disease Surveillane)Does your laboratory have a formally designated role in emergency response operations related to viral outbreaks or public health emergencies (e.g., inclusion in national or regional response plans)? Yes — formally designated in a national plan Yes — formally designated in a subnational/regional (state/provincial/territorial level) plan Yes — informally engaged in response efforts No — not currently designated, but interested in participating No — not involved in emergency response Other If “Yes,” please briefly describe your role and any agencies or partners you coordinate with:(Required)Please identify your laboratory’s designated role within national or multicountry emergency response structures. If there are none, please indicate.List key governmental or public health entities with which your laboratory has defined operational coordination during emergencies (e.g., Ministry of Health, National Public Health Institute, WHO/PAHO/Africa CDC, other countries’ public health agencies) If none, please indicate.If available, please provide contact information for the individuals responsible for emergency coordination within your lab (primary and alternate emails).If applicable, list any major or representative (up to 3) formal agreements with public health, clinical, or academic partners (e.g., MOU, DSA, DUA, MSA, joint protocols)Do you have jointly developed or shared SOPs with external partners for outbreak response or diagnostic workflows? Please provide if applicable Yes — briefly describe and list partners: No Yes — briefly describe and list partners:If relevant, please describe any regulatory or operational barriers that have complicated collaborations with public health agencies within nationally or internationally.Does your institution currently conduct, or have the capacity to conduct clinical trials related to virology? Yes — Currently running one or more virology-related clinical trials Yes — Have the infrastructure and regulatory approvals, but not currently running a virology trial No — Do not currently conduct virology-related trials and lack infrastructure Not sure Please list key pathogens or trial types in the space below. Section 5: Strategic Outlook & Challenges Do you have plans to grow your capacity in any particular viruses in the next 12 months? If so which ones? Yes No Yes (Capacity to grow - Which ones) Arboviruses Respiratory viruses Hemorrhagic fever viruses Enteric viruses Oncogenic viruses Zoonotic viruses Are there any new machines or diagnostic platforms currently on order or planned for acquisition at your center within the next 12 months? No new equipment currently on order Yes — PCR platforms (e.g., qPCR, digital PCR) Yes — Next-generation sequencers (e.g., Illumina, Oxford Nanopore, PacBio) Yes — Serology or immunoassay analyzers Yes — Point-of-care diagnostic devices Yes — High-throughput screening or automation systems Yes — Biosafety or containment infrastructure upgrades Other (please specify): Not sure Please list the specific equipment (make/model if known), estimated arrival date, and intended use:Are there specific viral pathogens of concern nationally or in the multicountry region? (Select all that apply and briefly explain why, if applicable.)(Required) Arboviruses (e.g., Dengue, Zika, Chikungunya, Oropouche) Respiratory viruses (e.g., SARS-CoV-2, Influenza, RSV) Hemorrhagic fever viruses (e.g., Lassa, Ebola, Marburg) Enteric viruses (e.g., Norovirus, Enteroviruses) Zoonotic spillover risks (e.g., Nipah, novel coronaviruses) Other (please specify): What makes these viruses particularly concerning in your region? For each selected category, briefly explain why.(Required)Other (new machines or diagnostic platforms)(Required)What are the major external challenges your institution faces in obtaining competitive funding for virology work? (Select all that apply and elaborate if possible.) Limited national funding opportunities for virology High competition for international grant programs Political or policy-related barriers to funding Lack of visibility or recognition of our institution Difficulty forming partnerships with high-income country collaborators Limited access to grant-writing support or mentorship Misalignment between funder priorities and local health needs Other (please specify): [Text box] Other (please specify major challenges)Please briefly describe how these challenges impact your work or ability to respond to emerging viral threatsIs your institution currently using artificial intelligence (AI) applications in any aspect of its virology work? (Select all that apply and provide brief details.) No, we are not currently using AI Yes, for diagnostics (e.g., image analysis, test interpretation) Yes, for surveillance and outbreak prediction Yes, for genomic analysis (e.g., sequence alignment, variant calling) Yes, for drug or vaccine discovery Yes, for data integration or decision support systems Yes, for administrative or operational efficiency Other (please specify): Other (Center currently using AI applications in any aspect of your work)(Required)Please describe any specific AI tools, platforms, or partnerships you're using: Section 6: Strategic Assessment Do you currently support a public health department or ministry of health? Yes, routinely Yes, occasionally Not currently, but interested Not currently, not a priority Which health entities do you work with? Ministry of Health National public health institute/reference laboratory Regional/state health authority Local/municipal health department Other (specify) Other (Health Entities)(Required)What types of support does your institution provide to the public health department or ministry of health? Routine diagnostic testing Surge diagnostic testing during outbreaks Genomic sequencing Bioinformatics/phylogenetics Data systems (LIMS integration, dashboards, automation) Joint surveillance design (sentinel or syndromic) Outbreak investigation support Training/short courses for PhD staff Mentorship or staff exchange (secondments) QMS/accreditation mentorship Risk communication support Policy or technical advisory roles Clinical trials support Other (specify) Other (What types of support)(Required)How formalized are your collaborations with the public health department or ministry of health? MOU/MSA Data Use Agreement Material Transfer Agreement Shared SOPs Joint governance or steering committee Informal only None Overall, how effective are your current public health department or ministry of health collaborations? Very effective Effective Mixed Ineffective No current collaborations What are the top three factors that enable effective collaboration for your organization? (Select up to 3)Select between 1 and 3 choices. Clear Mandates/roles Stable funding Fast contracting or procurement Data-sharing permissions IT interoperability Trust and relationships Leadership support (MOH/University) Share priorities and timelines Other (specify) Other ( Top 3 Factors)(Required)What resources could you offer the public health department or ministry of health during routine periods? (Select all that apply, estimates optional) PCR testing capacity (test/day) Sequencing capacity (genomes/months) Bioinformatics analysis supports (FTE available) Training seats per year Access to specialized equipment (specify) Access to biobank or specimen storage (specify) Staff time for outbreak response deployments None of the above Other Please estimate or explain your previous option(Required)Which areas are you most willing to expand for the public health department or ministry of health in the next 12-24 months? (rank top 3)Select exactly 3 choices. Diagnostics Genomic surveillance Bioinformatics Data systems Workforce training QMS/accreditation Field epidemiology/outbreak response Communications/community engagement Research or operational evaluation Other (specify) Other (expand public health)(Required)What would you need to expand that support?Select between 1 and 5 choices. Direct funding for staff Reagents or consumables IT investments Legal agreements or templates Faster procurement or contracting Access to specimens or metadata Government designation or mandate Training materials Other (specify) Other (Expand)(Required)What limits your current ability to support the public health department or ministry of health?Select between 1 and 5 choices. Limited FTE/competing academic duties Unsustainable funding model Slow grants or contracting processes IRB/ethics delays Limited data engineering capacity Limited QA/QMS maturity Restrictions on clinical testing or reporting Data-sharing or legal restrictions Government procurement or payment delays Political sensitivity or shifting priorities Specimen transport or import/export constraints Misaligned timelines (academic vs response) Publication restrictions Other (specify) Other (Limits)(Required)What are the top three threats to sustaining public health department or ministry of health support over the next 1-3 years?Select between 1 and 3 choices. Funding cuts Staff turnover Supply chain disruptions Cybersecurity incidents Natural disasters/extreme weather Public mistrust or misinformation Other (specify) Other (Threats)(Required)If a public health department or ministry of health asked for help tomorrow, what are the top two support packages you could deploy within 30 days?Would you participate in a regional network to share protocols, training, or data approaches? Yes Maybe No If “Yes”, what would you contribute? (training, sequencing, bioinformatics, QA panels, surge testing, convening, other)(Required)Would you be interested in being listed as an author on any publications that may result from this survey?(Required) Yes No
